RespireRx Pharmaceuticals Inc (RSPI)

[nakedmouse]

Let me get this straight; Cortex came up with a test that for 717, "triggers very consistently the artifact that we've seen". I assume this test was created in repsonse to the original FDA hold, yes?

Then Stole said "With the testing we've been able to do, it (717) certainly separates it from the other ampakines". Then he goes onto say "I can't tell you it's the only one we'll see with that (artifact)".

He also said regarding other compounds, "I would say there is still the uncertainty when we go 3 months, 6 months out...but that's not known"

Bottom line; They created a 717 specific test to prove the artifact wasn't just a one-off and, in fact, it turned out to be consistent. The testing (whatever that is) for every other compound may need to be done differently (and longer) and therefor they just don't know if this artifact issue will be ongoing.

Why would any one invest their hard earned money on such poor information?

Way to go Stoll!